TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: akinesia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ultrasound SVG minimal lumen area at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in ultrasound atheroma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative incidence of major adverse cardiac events
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life (QOF) elevating rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peripheral blood cell count (WBC, platelet, lymphocyte)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Killing activity of single peripheral karyocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean reductions in Young Mania Rating Scale (YMRS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom remission (YMRS score <= 12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wheelchair skills capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention to participate in a clinical trial
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of inflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of noninflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CSM-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Opting out likelihood
Endpoint domain: Life impact
Endpoint subdomain: Decision-making
Primary endpoint: Frequency of FMF peritonitis attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Survival period
Endpoint domain: Mortality/survival
Primary endpoint: Breastfeeding to any degree at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Exclusively breastfed at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in gastrointestinal tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Colonization rates
Endpoint domain: Adverse events/effects
Primary endpoint: Permanent venous abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Median effective dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiological outcomes
Primary endpoint: Diagnostic quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to antiretroviral therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of subjects with ≥1 acute vulvovaginal candidiasis episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lumbar BMD treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: femoral neck BMD treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of vertebral fracture
Endpoint domain: Adverse events/effects
Primary endpoint: Micromotion of uncemented cup
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hemodynamic parameters improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Shortened recovery time
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: lower pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent ipsilateral pneumothorax
Endpoint domain: Mortality/survival
Primary endpoint: multifidus muscle atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ghrelin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Knowledge test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Immediate renal graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: One year actuarial patient survival
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of developing DU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pedometer steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life score after treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of wheezing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of atopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean IIEF score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: residual joint dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chest compression flow fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pSTAT4 and IFN‐γ response of NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: irregularity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global health status improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fertilisation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Methemoglobin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of reflux episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of transient LES relaxations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Basal LES pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptoms of urinary urgency, frequency and incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximal contraction power and endurance of the pelvic floor muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean received tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of participants preferring modified BVM
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of myalgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: intubating conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: creatine kinase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Distant Disease-Free Survival (DDFS)
Endpoint domain: Mortality/survival
Primary endpoint: Protection against recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favourable outcome predicted by serum IL-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Musculoskeletal examination skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: CIWA scores on admission day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIWA scores on admission day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total lorazepam required to complete detoxification
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence and duration of severe oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily functioning activities (swallowing, drinking, eating, talking, sleeping)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Use of narcotic opioids
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median decline of FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Disease-free interval (DFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-relapse overall survival (RS)
Endpoint domain: Mortality/survival
Primary endpoint: Intentions to reduce sexual risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Tolerability of preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in HDRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gastric fluid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: phenol red retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reliability of Brasfield and NIH scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between radiographic scores and lung function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of obesity after 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Moderate-to-vigorous physical activity (MVPA) per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratings of importance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change from baseline in seated blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: regaining upper limb function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crestal bone height loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-implant bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiologic cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of clinical signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete AK clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: AK clearance of 75% or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: probability of sustained clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Successful anesthesia after the superior cluneal nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cessation Treatment Utilization (CTU)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Curve progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levodopa C(min) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0‐14) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levodopa C(max) profile consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cholesterol-HDL-C ratio reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death from cardiac reasons
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness of speech and language therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Normalization of skin colour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Physicians' improvement grading score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with undetectable plasma viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Late small bowel obstruction
Endpoint domain: Adverse events/effects
Primary endpoint: mean near-distance disparity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in bronchial asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decline in benefits on cessation of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of blood pressure to normal levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-therapy FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Attendance for cardiovascular risk assessment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fasting plasma FGF‐21 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of AF
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative levels of IL-6, IL-8, IL-10, CRP, and exhaled NO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative hospital length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Postparacentesis circulatory dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first readmission
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Survival
Endpoint domain: Mortality/survival
Endpoint subdomain: null
Primary endpoint: decreased rs-fc between LC and the thalamus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Modified Observer's Assessment of Alertness/Sedation (MOAA/S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transplantation-free survival at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Mean erythema scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Osmotic fragility of erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in arterial p(a)O(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the amount of ventilatory support needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of progression to severe PPHN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical resolution of psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathological resolution of epidermal hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clotting in the circuit
Endpoint domain: Adverse events/effects
Primary endpoint: Exposure to packed red blood cells
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Discontinuing care
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Postoperative levels of serum aspartate aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative levels of creatine kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: suppression of energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: knee extensor isokinetic strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak knee and hip flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to peak knee flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postallergen increase in sputum EG2-positive cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: maximum late percent fall in FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: diabetes-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: incidence rate of diarrheal episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ventilatory threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of EGCG
Endpoint domain: Adverse events/effects
Primary endpoint: Composite score of psoriasis signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum ACE activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PAI activity and PAI‐1 antigen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intraocular Pressure (IOP) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complicated urinary tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: Meatal stenosis
Endpoint domain: Adverse events/effects
Primary endpoint: Urethrocutaneous fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Overall infectious complications
Endpoint domain: Adverse events/effects
Primary endpoint: Major infectious complications
Endpoint domain: Adverse events/effects
Primary endpoint: Overall thrombotic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Functional Capacity (FC) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to flatus or stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time to resolution of abdominal distension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: DAS28(CRP) area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAQ score of 0
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: abnormal Pap smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: low-grade squamous intraepithelial lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in patients' knowledge and attitudes towards pain management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Use of nondrug interventions for pain management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in pain and back function parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capacity for daily tasks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: average symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average daily headache index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain relief before surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of fracture displacement during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction on the visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in Roland Morris questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients stopping medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mouth opening at suture removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital readmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate increase after intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: retirement from the study
Endpoint domain: Adverse events/effects
Primary endpoint: engagement in weight-management interventions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HADS anxiety scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SP/AP area curve ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of thrombotic occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ease of visualizing ureteral jets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of yellow-colored urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median constipation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stool form normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CL shortening or delivery within 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reablation rates
Endpoint domain: Mortality/survival
Primary endpoint: bile duct injury
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in EAPP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes